NCT07174453View on ClinicalTrials.gov

Trial to Evaluate irAEs With Different Standard of Care Dosing Strategies of Standard of Care Immunotherapies

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

192

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

October 1, 2027

Study Completion Date

October 1, 2029

Conditions

Solid Tumor Malignancies

Interventions

DRUG

Nivolumab

Immunotherapy

DRUG

Pembrolizumab

Immunotherapy

All Listed Sponsors

lead

University of Kansas Medical Center

OTHER